

Announcement Summary

Entity name

RADIOPHARM THERANOSTICS LIMITED

Announcement Type

New announcement

Date of this announcement

Thursday September 17, 2026

The +securities to be quoted are:

Other

Please refer to the response to Q2.3d for further information about the type of securities to be quoted and the circumstances of the issue.

Appendix 3B issued 24 July 2026 including new class of option to be quoted

Total number of +securities to be quoted

ASX +security code	Security description	Number of +securities to be quoted	Issue date
RAD	ORDINARY FULLY PAID	333,333,299	17/09/2026
New class - code to be confirmed	OPTION EXPIRING 31-JUL-2029 EX 0.018	333,333,299	17/09/2026
New class - code to be confirmed	OPTION EXPIRING 31-JUL-2029 EX 0.018	200,000,000	17/09/2026

Refer to next page for full details of the announcement

Part 1 - Entity and announcement details

1.1 Name of entity

RADIOPHARM THERANOSTICS LIMITED

We (the entity named above) apply for +quotation of the following +securities and agree to the matters set out in Appendix 2A of the ASX Listing Rules.

1.2 Registered number type

ACN

Registration number

647877889

1.3 ASX issuer code

RAD

1.4 The announcement is

New announcement

1.5 Date of this announcement

17/9/2026

Part 2 - Type of Issue

2.1 The +securities to be quoted are:

Other

Please refer to the response to Q2.3d for further information about the type of securities to be quoted and the circumstances of the issue.

2.2 The +class of +securities to be quoted is:

Additional +securities in a class that is already quoted on ASX ("existing class")

New +securities in a class that is not yet quoted on ASX ("new class")

2.3c Have these +securities been offered under a +disclosure document or +PDS?

Yes

2.3c.1 Date of +disclosure document or +PDS?

30/7/2026

2.3d Please provide any further information needed to understand the circumstances in which you are applying to have these +securities quoted on ASX, including why the issue of the +securities has not been previously announced to the market in an Appendix 3B

Appendix 3B issued 24 July 2026 including new class of option to be quoted

Part 3B - number and type of +securities to be quoted (existing class) where issue has not previously been notified to ASX in an Appendix 3B

Additional +securities to be quoted in an existing class

ASX +security code and description

RAD : ORDINARY FULLY PAID

Issue date

17/9/2026

Will the +securities to be quoted rank equally in all respects from their issue date with the existing issued +securities in that class?

Yes

Issue details

Number of +securities to be quoted

333,333,299

Are the +securities being issued for a cash consideration?

Yes

In what currency is the cash consideration being paid? What is the issue price per +security?

AUD - Australian Dollar

AUD 0.00900000

Any other information the entity wishes to provide about the +securities to be quoted

Shares under Share Purchase Plan announced 24 July 2026 and approved by shareholders at EGM held 11 September 2026

The purpose(s) for which the entity is issuing the securities

Other

Please provide additional details

The proceeds will primarily be used to fund drug manufacturing, clinical trials and working capital.

Part 3C - number and type of +securities to be quoted (new class) where issue has not previously been notified to ASX in an Appendix 3B

New +securities

ASX +security code

New class - code to be confirmed

+Security description

OPTION EXPIRING 31-JUL-2029 EX 0.018

+Security type

Options

ISIN code

Issue date

17/9/2026

Will all the +securities issued in this class rank equally in all respects from the issue date?

Yes

Have you received confirmation from ASX that the terms of the +securities are appropriate and equitable under listing rule 6.1?

No

Distribution Schedule

Provide a distribution schedule for the new +securities according to the categories set out in the left hand column - including the number of recipients and the total percentage of the new +securities held by the recipients in each category.

Number of +securities held	Number of holders	Total percentage of +securities held For example, to enter a value of 50% please input as 50.00
1 - 1,000		%
1,001 - 5,000		%
5,001 - 10,000		%
10,001 - 100,000	1	0.01 %
100,001 and over	135	99.99 %

Options Details

+Security currency

AUD - Australian Dollar

Exercise price

AUD 0.01800000

Expiry date

31/7/2029

Details of the type of +security that will be issued if an option is exercised

RAD : ORDINARY FULLY PAID

Number of +securities that will be issued if an option is exercised

One RAD ordinary full paid share for each option exercised

Please provide a URL link for a document lodged with ASX setting out the material terms of the +securities to be quoted or provide the information by separate announcement.

Prospectus dated 30 July 2026

<https://asx.api.cmfyapp.com/asx-research/1.0/file/2924-03116015-2A1686719&v=undefined>

Issue details

Number of +securities to be quoted

333,333,299

Are the +securities being issued for a cash consideration?

No

Please describe the consideration being provided for the +securities

Options under Share Purchase Plan announced 24 July 2026 and approved by shareholders at EGM held 11 September 2026

Please provide an estimate (in AUD) of the value of the consideration being provided per +security for the +securities to be quoted

0.000000

Any other information the entity wishes to provide about the +securities to be quoted**The purpose(s) for which the entity is issuing the securities**

Other

Please provide additional details

The proceeds will primarily be used to fund drug manufacturing, clinical trials and working capital

New +securities**ASX +security code**

New class - code to be confirmed

+Security description

OPTION EXPIRING 31-JUL-2029 EX 0.018

+Security type

Options

ISIN code**Issue date**

17/9/2026

Will all the +securities issued in this class rank equally in all respects from the issue date?

Yes

Have you received confirmation from ASX that the terms of the +securities are appropriate and equitable under listing rule 6.1?

No

Distribution Schedule

Provide a distribution schedule for the new +securities according to the categories set out in the left hand column - including the number of recipients and the total percentage of the new +securities held by the recipients in each category.

Number of +securities held	Number of holders	Total percentage of +securities held For example, to enter a value of 50% please input as 50.00
1 - 1,000		%
1,001 - 5,000		%
5,001 - 10,000		%
10,001 - 100,000	1	0.01 %
100,001 and over	135	99.99 %

Options Details

+Security currency	Exercise price	Expiry date
AUD - Australian Dollar	AUD 0.01800000	31/7/2029

Details of the type of +security that will be issued if an option is exercised

RAD : ORDINARY FULLY PAID

Number of +securities that will be issued if an option is exercised

One RAD ordinary full paid share for each option exercised

Please provide a URL link for a document lodged with ASX setting out the material terms of the +securities to be quoted or provide the information by separate announcement.

Prospectus dated 30 July 2026

<https://asx.api.cmfyapp.com/asx-research/1.0/file/2924-03116015-2A1686719&v=undefined>

Issue details

Number of +securities to be quoted

200,000,000

Are the +securities being issued for a cash consideration?

No

Please describe the consideration being provided for the +securities

Component of shortfall commitment fee in relation to SPP announced 24 July 2026 and approved by shareholders at EGM held 11 September 2026

Please provide an estimate (in AUD) of the value of the consideration being provided per +security for the +securities to be quoted

0.000000

Any other information the entity wishes to provide about the +securities to be quoted

The purpose(s) for which the entity is issuing the securities

Other

Please provide additional details

The proceeds will primarily be used to fund drug manufacturing, clinical trials and working capital

Part 4 - Issued capital following quotation

Following the quotation of the +securities the subject of this application, the issued capital of the entity will comprise:

The figures in parts 4.1 and 4.2 below are automatically generated and may not reflect the entity's current issued capital if other Appendix 2A, Appendix 3G or Appendix 3H forms are currently with ASX for processing.

4.1 Quoted +securities (total number of each +class of +securities quoted on ASX following the +quotation of the +securities subject of this application)

ASX +security code and description	Total number of +securities on issue
RADO : OPTION EXPIRING 30-NOV-2026	79,352,040
RAD : ORDINARY FULLY PAID	4,670,882,790
RADOB : OPTION EXPIRING 31-OCT-2027	1,179,266,658
New class - code to be confirmed : OPTION EXPIRING 31-JUL-2029 EX 0.018	333,333,299
New class - code to be confirmed : OPTION EXPIRING 31-JUL-2029 EX 0.018	200,000,000

4.2 Unquoted +securities (total number of each +class of +securities issued but not quoted on ASX)

ASX +security code and description	Total number of +securities on issue
RADAK : OPTION EXPIRING 01-JUN-2027 EX \$0.60	1,666,500
RADAN : OPTION EXPIRING VARIOUS DATES EX VARIOUS PRICES	387,179,525
RADAJ : OPTION EXPIRING 01-JUL-2027 EX \$0.17	12,425,675
RADAF : OPTION EXPIRING 25-NOV-2026 RESTRICTED	8,666,678
RADAG : OPTION EXPIRING 25-NOV-2026 EX \$0.60	5,066,672
RADAI : OPTION EXPIRING 27-MAY-2027 EX \$0.60	740,000
RADAP : OPTION EXPIRING 24-APR-2028 EX \$0.09	8,955,224

Part 5 - Other Listing Rule requirements

5.1 Are the +securities being issued under an exception in Listing Rule 7.2 and therefore the issue does not need any security holder approval under Listing Rule 7.1?

Yes

5.1a Select the number of the applicable exception in Listing Rule 7.2

17